Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Recruiting · NCT07581808 · Registry updated 2026-06-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Recruiting | Phase 4 | 2026-06-02 | NCT07581808 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Medical Centre Ljubljana | 81 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Medical Centre Ljubljana | Ljubljana | Slovenia | 35 |